Nevro Corp. (NYSE:NVRO) in our automated value investing analysis, with the cash flow history and price comparison below.
Advertisement helps keep Trendshare free for most readers.
Estimate how long you need to hold Nevro Corp. to reach your target.
Hmm, we can't give any reliable projection for Nevro Corp.'s growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.
None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!
| Advantages | Disadvantages | Neutral |
|---|---|---|
| None. |
|
|
| NVRO Price (Nevro Corp. stock price per share) |
$0.00 | |
| PE Ratio versus Sector | 100% lower than other Healthcare stocks | |
| PE Ratio versus Industry | 100% lower than other Medical Devices stocks | |
| Free Cash Flow Jitter | 86% |
No open-market insider buys or sells are recorded for the last 12 months.
Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth
How to read this: free cash flow in plain terms, free cash flow jitter.
How to read this: what free cash flow is, why earnings matter.
Over the 1 fiscal years from 2012 to 2024 with positive net income, operating cash flow totaled $24.7 million against net income of $3 million, or 8.22 times. Net income was negative in 12 of the 13 years, and those years are left out of the ratio.
In 2024, net income was -$113 million and operating cash flow was -$19.4 million, so no ratio is shown for that year.
In 2022, capital expenditures were $7.5 million, 30.6% of operating cash flow of $24.7 million, which leaves an estimated $17.1 million after capex. Across the 2 years with reported capex, it averaged 52.5% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.
| Fiscal year | Net income (USD millions) | Operating cash flow (USD millions) | Capital expenditures (USD millions) | Operating cash flow / net income |
|---|---|---|---|---|
| 2012 | -19 | -22.5 | 0 | n/a |
| 2013 | -26 | -21.1 | 0.1 | n/a |
| 2014 | -30.7 | -31.1 | 0.6 | n/a |
| 2015 | -67.4 | -100 | 5 | n/a |
| 2016 | -31.8 | -58.5 | 3.4 | n/a |
| 2017 | -36.7 | -14.3 | 4.3 | n/a |
| 2018 | -49.2 | -5.7 | 8.2 | n/a |
| 2019 | -104 | -50.2 | 3.5 | n/a |
| 2020 | -83.1 | 1.2 | 6 | n/a |
| 2021 | -131 | -41.9 | 12.3 | n/a |
| 2022 | 3 | 24.7 | 7.5 | 8.22 |
| 2023 | -92.2 | -58.8 | 8.6 | n/a |
| 2024 | -113 | -19.4 | 9.8 | n/a |
How to read this: earnings and margins.
Revenue was $18.1 million in 2012 and $409 million in 2024, a compound annual growth rate of 29.6% over 12 years. The starting revenue was under 10% of the latest, so that rate comes from a small base and says little about recent growth.
Revenue fell 3.9% from 2023 to 2024.
Our estimated free cash flow was -$28.3 million in 2024, a negative margin of 6.9% of revenue, meaning the estimate was below zero. In 2012 the estimated margin was negative 124.0%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.
| Fiscal year | Revenue (USD millions) | Estimated free cash flow (USD millions) | Estimated free cash flow / revenue |
|---|---|---|---|
| 2012 | 18.1 | -22.5 | -124.0% |
| 2013 | 23.5 | -21.1 | -89.9% |
| 2014 | 32.6 | -31.4 | -96.4% |
| 2015 | 69.6 | -102 | -146.3% |
| 2016 | 229 | -60.3 | -26.4% |
| 2017 | 327 | -16.9 | -5.2% |
| 2018 | 387 | -10 | -2.6% |
| 2019 | 390 | -55.1 | -14.1% |
| 2020 | 362 | -3.9 | -1.1% |
| 2021 | 387 | -48.8 | -12.6% |
| 2022 | 406 | 17.2 | 4.2% |
| 2023 | 425 | -66.4 | -15.6% |
| 2024 | 409 | -28.3 | -6.9% |
How to read this: how debt and assets are compared, the current ratio.
In 2024, cash and equivalents were $94.5 million against total liabilities of $323 million, or 29.3% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.
Total liabilities were 58.3% of total assets in 2024, compared with 213.8% in 2013, a decrease of 155.5 percentage points.
Stockholders equity was $231 million in 2024, up from negative equity of -$85.8 million in 2013.
Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was -7.9% in 2024. Invested capital here is total assets less cash and current liabilities.
| Fiscal year | Total assets (USD millions) | Cash and equivalents (USD millions) | Total liabilities (USD millions) | Stockholders equity (USD millions) |
|---|---|---|---|---|
| 2013 | 75.4 | 12.4 | 161 | -85.8 |
| 2014 | 202 | 25.3 | 30.4 | 172 |
| 2015 | 291 | 87 | 56.6 | 235 |
| 2016 | 431 | 41.4 | 182 | 249 |
| 2017 | 454 | 42.8 | 205 | 249 |
| 2018 | 463 | 51.3 | 218 | 245 |
| 2019 | 470 | 65.4 | 253 | 216 |
| 2020 | 789 | 44.6 | 401 | 388 |
| 2021 | 575 | 34.7 | 271 | 304 |
| 2022 | 602 | 120 | 279 | 324 |
| 2023 | 636 | 104 | 343 | 293 |
| 2024 | 554 | 94.5 | 323 | 231 |
Only 1 of the 13 fiscal years under Nevro Corp.'s current filer show positive free cash flow.
We do not estimate a fair value for Nevro Corp. while its free cash flow growth is not positive, so there is no value comparison here.
Year-to-year variability in free cash flow is volatile, measured at 86%.
We do not have a dividend yield for Nevro Corp..
These figures are automated calculations from SEC filings and the recent price. They are not a recommendation to buy or sell. See how we estimate value.
How to read this: the price to earnings ratio.
Its trailing P/E ratio is 100% below the average for stocks in the Healthcare sector.
Its trailing P/E ratio is 100% below the average for stocks in the Medical Devices industry.
A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.
These are companies in the Medical Devices industry, the ones closest in market capitalization to Nevro Corp., limited to companies whose pages we publish. The figures come from our latest data for each company.
| Company | Market cap (USD millions) | P/E | Dividend yield | Cash yield | Price versus our estimate |
|---|---|---|---|---|---|
| Nevro Corp. (NVRO) | - | - | - | - | - |
| Baxter International (BAX) | 13,135 | - | 0.2% | 11.4% | 61% below |
| Boston Scientific Corporation (BSX) | 60,849 | 17.7 | - | 1.9% | 49% above |
| CONMED Corporation (CNMD) | 1,382 | 19.2 | - | 5.6% | 35% below |
| DexCom (DXCM) | 29,582 | 31.2 | - | 0.1% | 864% above |
| Electromed (ELMD) | 188 | 16.7 | - | - | 248% above |
| Globus Medical (GMED) | 8,861 | 16.5 | - | - | 61% above |
Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.
Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.
Every fiscal year on this page is reported by one SEC filer, CIK 1444380.
Each figure on this page comes from that filer.
How to read this: understanding investment risk.
Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.
Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.
The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.
This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.
Read the filings yourself: NVRO annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.
Advertisement supports free stock analysis content.
Does Nevro Corp. have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
This example shows how we apply the Trendshare checklist to NVRO: earnings power, cash generation, valuation, and margin of safety.
We check: business quality, free cash flow, P/E, and margin of safety.
Most Popular Articles
What is the Difference Between Trading Stocks and Investing?
Why Do Companies Perform Stock Buybacks?
How Does Portfolio Churning Affect Your Returns?
How Do Tariffs Affect the Stock Market?
DCA vs Lump Sum: 155 Years of S&P 500 Historical Data
How to Invest $1000 in the Stock Market